Ribavirin

doi:10.1016/b978-0-444-53717-1.01403-7

Cited by 1 publication

(2 citation statements)

References 122 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The potential antiviral activity is due to the conversion of ribavirin into its active 5'-phosphate derivatives and the deribosylated base, which hinders the capping and elongation of mRNA. [71] In in vitro studies, ribavarin shows activity against various DNA and RNA viruses like paramyxoviruses, myxoviruses, bunyaviruses, poxviruses, retroviruses, herpesviruses, and adenoviruses. [72] Ribavirin administration route can be intravenous, oral, or by aerosol; the latter two formulations (Virazole) of the drug are sanctioned for use in the United States of America.…”

Section: Nucleoside and Nucleotide Analogues As Hepatitis Polymerase Inhibitorsmentioning

confidence: 99%

“…It is teratogenic and embryotoxic in in vivo studies and hence, unsafe for pregnant women. [71] Adefovir dipivoxil is an acyclic adenosine nucleotide analogue and needs single phosphorylation before successfully competing with adenosine for incorporation into HBV DNA thereby causing chain termination. Adefovir was primarily approved as anti-HIV medication with a dosage of 60 mg daily.…”

Section: Nucleoside and Nucleotide Analogues As Hepatitis Polymerase Inhibitorsmentioning

confidence: 99%

See 1 more Smart Citation

Advances in Nucleoside and Nucleotide Analogues in Tackling Human Immunodeficiency Virus and Hepatitis Virus Infections

2021

View full text Add to dashboard Cite

Nucleoside and nucleotide analogues are structurally similar antimetabolites and are promising small‐molecule chemotherapeutic agents against various infectious DNA and RNA viruses. To date, these analogues have not been documented in‐depth as anti‐human immunodeficiency virus (HIV) and anti‐hepatitis virus agents, these are at various stages of testing ranging from pre‐clinical, to those withdrawn from trials, or those that are approved as drugs. Hence, in this review, the importance of these analogues in tackling HIV and hepatitis virus infections is discussed with a focus on the viral genome and the mechanism of action of these analogues, both in a mutually exclusive manner and their role in HIV/hepatitis coinfection. This review encompasses nucleoside and nucleotide analogues from 1987 onwards, starting with the first nucleoside analogue, zidovudine, and going on to those in current clinical trials and even the drugs that have been withdrawn. This review also sheds light on the prospects of these nucleoside analogues in clinical trials as a treatment option for the COVID‐19 pandemic.

show abstract

Section: Nucleoside and Nucleotide Analogues As Hepatitis Polymerase Inhibitorsmentioning

confidence: 99%

Section: Nucleoside and Nucleotide Analogues As Hepatitis Polymerase Inhibitorsmentioning

confidence: 99%

Advances in Nucleoside and Nucleotide Analogues in Tackling Human Immunodeficiency Virus and Hepatitis Virus Infections

2021

View full text Add to dashboard Cite

show abstract

Ribavirin

Cited by 1 publication

References 122 publications

Advances in Nucleoside and Nucleotide Analogues in Tackling Human Immunodeficiency Virus and Hepatitis Virus Infections

Advances in Nucleoside and Nucleotide Analogues in Tackling Human Immunodeficiency Virus and Hepatitis Virus Infections

Contact Info

Product

Resources

About